New Treatment Strategies in Active Multiple Myeloma - prIME Oncology
Expert Review
Expert Review

New Treatment Strategies in Active Multiple Myeloma

A Shifting Paradigm

Not a member of My prIME? Join now for instant access.

Explore the evolving treatment landscape in multiple myeloma (MM). Expert thought leaders provide details about current standard of care in front-line treatment and for patients with heavily pretreated disease, recent publications on novel agents and combinations, and a detailed discussion of toxicity management with the novel agents.

This activity also includes a downloadable resource on the safety issues of select novel agents. Click here to download the adverse events handout.

Interactive Presentation

Interactive Presentation

CME

CME

1.25 AMA PRA Category 1 Credit(s)™

Release Date

Release Date

Apr 15, 2019

Expiration Date

Apr 15, 2020

  • Ola C. Landgren, MD, PhDMemorial Sloan Kettering Cancer Center
    New York City, New York, United States
  • Ruben Niesvizky, MDWeill Cornell Medicine
    New York, New York, United States
  • Transplant-Ineligible MM
  • Transplant-Eligible MM
  • Relapsed/Refractory MM

This educational program is designed to address challenges experienced by hematologists, oncologists, and other healthcare professionals who manage patients with MM.

After successful completion of this educational activity, participants should be able to:

  • Determine optimal treatment for newly diagnosed active multiple myeloma based on patient and disease characteristics
  • Select appropriate treatment for patients with previously treated and heavily pretreated multiple myeloma
  • Implement strategies for the monitoring and management of adverse events and associated with approved and novel treatments

This educational activity is supported by a grant from AbbVie.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This educational activity is supported by a grant from AbbVie.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.25 hours

To contact Postgraduate Institute for Medicine, please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Landgren has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Niesvizky has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer
  • Briana Betz, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
  • Susan McKinney – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.